At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized Clinical Study Comparing Triple Therapy Regimen to Hydrocortisone Monotherapy in Reducing Mortality in Septic Shock Patients
In Brief
A Phase 3 clinical trial evaluating vitamin c - thiamine- hydrocortisone for Septic Shock and 2 related conditions. Completed, enrolled 94 participants across 1 site.
Detailed Summary
this study is conducted to evaluate the role of the novel triple therapy combination in reducing the mortality rate, reducing the shock time, and reversal of organ damage. the study includes two arms, the first arm is the control which received hydrocortisone monotherapy and the second arm is the intervention arm which received the triple therapy regimen. calculation of 28 days in-hospital mortality is the primary outcome. shock time, vasopressor doses, infection markers, and organ function tests are the secondary outcomes. the data will be analyzed by student t-test or Mann Whitney test, Fischer exact or chi-square test for numbers, repeated measures ANOVA will be used to consider confounders and other parameters, mortality will be expressed by Kaplan Meier and ROC curve. For Multivariate analysis of repeated quantitative outcomes, linear mixed models were used to quantify the relationship between one dependent variable (SOFA, SCr, doses of vasopressors) and many independent variables including group type and sepsis phenotype adjusted to other clinical and demographic factors.
Study Details
Timeline
Interventions
Triple therapy regimen (vitamin c - thiamine- hydrocortisone)